Sugi Predict

Sugi Predict / Compounds / SCHEMBL3097463

SCHEMBL3097463

SCHEMBL3097463

CCN(C(=O)C(Cc1cnn(Cc2ccc(F)cc2)c1)C(=O)NS(=O)(=O)/C=C/c1ccccc1)c1ccccc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.40
▸ HDAC2 Q92769 2/20 0.37
▸ TCF4 P15884 1/20 0.34
▸ CTNNB1 P35222 1/20 0.34
▸ KMT2A Q03164 2/20 0.34
▸ PKM P14618 1/20 0.34
▸ ALDH1A1 P00352 3/20 0.34
▸ MAPT P10636 2/20 0.34
▸ HTT P42858 2/20 0.34
▸ MAPK1 P28482 1/20 0.34
▸ GBA1 P04062 1/20 0.34
▸ SMN1; SMN2 Q16637 2/20 0.33
▸ POLB P06746 1/20 0.33
▸ KDM4E B2RXH2 1/20 0.33
▸ HPGD P15428 1/20 0.33
▸ HSD17B10 Q99714 1/20 0.33
▸ HDAC3 O15379 1/20 0.33
▸ JAK2 O60674 1/20 0.33
▸ HDAC4 P56524 1/20 0.33
▸ HDAC1 Q13547 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3097471 1.00 LMNA (0.40) LMNAHDAC2TCF4CTNNB1KMT2A
SCHEMBL3078964 0.97 LMNA (0.39) LMNAHDAC2TCF4CTNNB1KMT2A
SCHEMBL3078960 0.97 LMNA (0.39) LMNAHDAC2TCF4CTNNB1KMT2A
SCHEMBL3090762 0.97 LMNA (0.39) LMNAHDAC2TCF4CTNNB1KMT2A
SCHEMBL3090767 0.97 LMNA (0.39) LMNAHDAC2TCF4CTNNB1KMT2A
SCHEMBL3092554 0.94 HDAC2 (0.35) LMNAHDAC2ALDH1A1HTTPOLB
SCHEMBL3092559 0.94 HDAC2 (0.35) LMNAHDAC2ALDH1A1HTTPOLB
SCHEMBL3090430 0.93 LMNA (0.36) LMNAHDAC2TCF4CTNNB1KMT2A
SCHEMBL3090431 0.93 LMNA (0.36) LMNAHDAC2TCF4CTNNB1KMT2A
SCHEMBL3090462 0.91 LMNA (0.42) LMNAHDAC2TCF4CTNNB1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2172450-B9 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2014-10-08 — — EP disclosed
EP-2172450-B1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2013-10-16 — — EP disclosed
US-8461209-B2 Malonic acid sulfonamide derivative and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-06-11 — — US disclosed
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-09-09 — — US disclosed
EP-2172450-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF Mitsubishi Tanabe Pharma Corporation (JP) 2010-04-07 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF REN, AGTR2, AGTR1 LMNA 3803/4885HDAC2 1497/4885TCF4 4135/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.